Exploring Medically Perceived Benefits, Use and Interest in Psychedelics and Cannabinoids

NCT04965740 | Completed DMC FDA Drug

• 1 other identifier: EMP-SURVEY-001
• Study Type: observational
• Target: 102
• Locations: 1 country
• Sites: 1

Brief Summary

The primary objective of this study is to collect insights from first responders and military personnel on their need for, use of, and interest in physical and/or mental health medical marijuana or psychedelic-assisted therapy programs. These preliminary data will help to inform and guide the development of a larger patient-oriented study and the design of a clinical program geared towards enhancing therapy treatments for first responders and military personnel.

Conditions

PTSD; Anxiety; Anxiety Disorders; Depression; Depressive Disorder; Psychological; Psychedelic Experiences; Psychedelic Drug Dependence

Outcome Measures

Primary Outcomes (1)

• Collect Insights from First Responders

  The primary objective of this study is to collect insights from first responders and military personnel on their need for, use of, and interest in physical and/or mental health medical marijuana or psychedelic-assisted therapy programs. These preliminary data will help to inform and guide the development of a larger patient-oriented study and the design of a clinical program geared towards enhancing therapy treatments for first responders and military personnel.

  8 months

Study Arms (2)

North American First Responders

Spread directly to union representatives for email and messaging to those interested in taking the survey

Drug: Cannabis

Oceana and European first responders

First responder unions and groups that are located outside of North America - particularly Australia, New Zealand, United Kingdom, other commonwealth nations.

Drug: Cannabis

Interventions

Cannabis DRUG

Recreational Cannabis

Also known as: Recreational Cannabis

North American First Responders; Oceana and European first responders

Eligibility Criteria

• Age: 19 Years - 85 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Approximately 10,000 first responders and/or military personnel will be asked to participate in the survey. Assuming a 20-30% response rate, the investigators expect approximately 2500 individual responses.

You may qualify if:

• Adult (19+) first responders and military personnel in Canada, USA, Oceana and Europe -
• Not restricted by restricted by sex, gender, or diagnoses.
• Respondents must be able to read and write in English to participate.

You may not qualify if:

• Individuals who are not first responders, military personnel, or an aligned profession
• Individuals under the age of 19
• Those who are not able to read and write in English

Sponsors & Collaborators

• Empower Research Inc: lead

Study Sites (1)

Centre for Neurology Studies

Surrey, British Columbia, V3V 0C6, Canada

Location

Related Publications (5)

• Brunello N, Davidson JR, Deahl M, Kessler RC, Mendlewicz J, Racagni G, Shalev AY, Zohar J. Posttraumatic stress disorder: diagnosis and epidemiology, comorbidity and social consequences, biology and treatment. Neuropsychobiology. 2001;43(3):150-62. doi: 10.1159/000054884.

  PMID: 11287794 BACKGROUND

• Marmar CR, McCaslin SE, Metzler TJ, Best S, Weiss DS, Fagan J, Liberman A, Pole N, Otte C, Yehuda R, Mohr D, Neylan T. Predictors of posttraumatic stress in police and other first responders. Ann N Y Acad Sci. 2006 Jul;1071:1-18. doi: 10.1196/annals.1364.001.

  PMID: 16891557 BACKGROUND

• Jerome L, Feduccia AA, Wang JB, Hamilton S, Yazar-Klosinski B, Emerson A, Mithoefer MC, Doblin R. Long-term follow-up outcomes of MDMA-assisted psychotherapy for treatment of PTSD: a longitudinal pooled analysis of six phase 2 trials. Psychopharmacology (Berl). 2020 Aug;237(8):2485-2497. doi: 10.1007/s00213-020-05548-2. Epub 2020 Jun 4.

  PMID: 32500209 BACKGROUND

• Passie T, Emrich HM, Karst M, Brandt SD, Halpern JH. Mitigation of post-traumatic stress symptoms by Cannabis resin: a review of the clinical and neurobiological evidence. Drug Test Anal. 2012 Jul-Aug;4(7-8):649-59. doi: 10.1002/dta.1377. Epub 2012 Jun 26.

  PMID: 22736575 BACKGROUND

• Gasser P, Holstein D, Michel Y, Doblin R, Yazar-Klosinski B, Passie T, Brenneisen R. Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases. J Nerv Ment Dis. 2014 Jul;202(7):513-20. doi: 10.1097/NMD.0000000000000113.

  PMID: 24594678 BACKGROUND

Related Links

• Survey Link

MeSH Terms

Conditions

Stress Disorders, Post-Traumatic; Anxiety Disorders; Depression; Depressive Disorder

Interventions

nabiximols

Condition Hierarchy (Ancestors)

Stress Disorders, Traumatic; Trauma and Stressor Related Disorders; Mental Disorders; Behavioral Symptoms; Behavior; Mood Disorders

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: CROSS SECTIONAL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: July 4, 2021
• First Posted: July 16, 2021
• Study Start: June 4, 2021
• Primary Completion: February 4, 2022
• Study Completion: February 15, 2022
• Last Updated: August 12, 2022

Record last verified: 2022-08

Locations

CA (1)